Clinical Sciences Department, Faculté de Médecine Vétérinaire, Université de Montréal. 3200 Sicotte Saint-Hyacinthe, J2S 7C6, Quebec, Canada.
Equine Vet J. 2010 May;42(4):316-21. doi: 10.1111/j.2042-3306.2009.00022.x.
Orally administered prednisolone and dexamethasone are used commonly in the treatment of recurrent airway obstruction (RAO) in horses. However, the efficacy of prednisolone in improving pulmonary function during continuous antigen exposure has not been evaluated critically and there is little evidence supporting the efficacy of low-dose oral dexamethasone in the same conditions.
Oral prednisolone and dexamethasone improve pulmonary function in RAO under conditions of continuous antigen exposure, and dexamethasone is more effective than prednisolone at commonly used dosages.
Using a randomised crossover design, prednisolone (2 mg/kg bwt) and dexamethasone (0.05 mg/kg bwt) were administered per os, s.i.d. for 7 days, to 7 horses during clinical exacerbation of the disease. Maximal difference in transpulmonary pressure (DeltaP(L)), lung resistance (R(L)) and elastance (E(L)) were measured before and after 3 and 7 days of treatment.
Prednisolone and dexamethasone improved pulmonary function significantly. However, the improvement was of greater magnitude after 3 and 7 days of treatment with dexamethasone compared to prednisolone. Also, after 7 days of treatment with dexamethasone, DeltaP(L) and R(L) were not different from values obtained when horses were on pasture, while all 3 pulmonary function parameters remained different from pasture values after prednisolone treatment.
Both corticosteroids improve pulmonary function, in spite of continuous antigen exposure. However, oral dexamethasone at 0.05 mg/kg bwt is more effective than prednisolone at 2 mg/kg bwt in the treatment of RAO.
Prednisolone was shown, for the first time, to our knowledge, to improve the pulmonary function of horses with RAO in the presence of continuous antigen exposure. This study also demonstrates the efficacy of low-dose oral dexamethasone in reversing airway obstruction in these conditions.
泼尼松龙和地塞米松经口给药常用于治疗马复发性气道阻塞(RAO)。然而,泼尼松龙在持续抗原暴露时改善肺功能的疗效尚未得到严格评估,并且几乎没有证据支持在相同条件下低剂量口服地塞米松的疗效。
在持续抗原暴露的情况下,口服泼尼松龙和地塞米松可改善 RAO 的肺功能,并且在常用剂量下,地塞米松比泼尼松龙更有效。
使用随机交叉设计,在疾病临床恶化期间,7 匹马每天口服泼尼松龙(2mg/kg bwt)和地塞米松(0.05mg/kg bwt),s.i.d.,共 7 天。在治疗前、治疗后 3 天和 7 天测量跨肺压(DeltaP(L))、肺阻力(R(L))和弹性(E(L))的最大差异。
泼尼松龙和地塞米松均显著改善肺功能。然而,与泼尼松龙相比,地塞米松治疗 3 天和 7 天后改善程度更大。此外,在接受地塞米松治疗 7 天后,DeltaP(L)和 R(L)与马在牧场上时的值没有差异,而在用泼尼松龙治疗后,所有 3 个肺功能参数仍与牧场上的值不同。
尽管存在持续的抗原暴露,但这两种皮质类固醇都能改善肺功能。然而,口服地塞米松 0.05mg/kg bwt 比泼尼松龙 2mg/kg bwt 更有效地治疗 RAO。
据我们所知,泼尼松龙首次被证明可改善持续抗原暴露时 RAO 马的肺功能。本研究还证明了在这些条件下低剂量口服地塞米松逆转气道阻塞的疗效。